FORMULATION AND EVALUATION OF SELF-EMULSIFYING DRUG DELIVERY SYSTEM OF ETORICOXIB

Objective: In the present dissertation work, the aim was to prepare self-emulsifying drug delivery systems (SEDDS) of etoricoxib to improve its solubility with a view to enhance its oral bioavailability.Methods: The prepared SEDDS was the concentrate of drug, oil, surfactants, and cosurfactant. The formulation was evaluated for various tests such as solubility, globule size, thermodynamic stability study, pH determination, ease of dispersibility, uniformity index, drug content, in-vitro release study, and in-vitro permeation study.Results: The optimized formulation F6 showed drug release (79.21±2.73%), droplet size (0.546 μm). In vitro drug release of the F6 was highly significant (p<0.05) as compared to the plain drug.Conclusion: All formulations of etoricoxib SEDDS were showed faster dissolution than plain drug (p<0.05), mean bioavailability of etoricoxib increase in respect to the plain drug. The F6 can be further used for the preparation of various solid SEDDS formulations

RP-HPLC Method for Simultaneous Estimation of Frusemide and Amiloride Hydrochloride in Tablet Formulation

A new reverse phase high performance liquid chromatography method for the simultaneous estimation of frusemide and amiloride hydrochloride in tablet formulation is developed. The determination was carried out on a HIQ SIL, C18 (250×4.6 mm, 5 µm) column using a mobile phase of 50 mM phosphate buffer solution:acetonitrile (50:50 v/v, pH 3.0). The flow rate was 1.0 ml/min with detection at 283 nm. The retention time for frusemide was 3.038 min and for amiloride hydrochloride 10.002 min. Frusemide and amiloride hydrochloride showed a linear response in the concentration range of 20-200 µg/ml and 10-100 µg/ml, respectively. The results of analysis have been validated statistically and by recovery studies. The mean recoveries found for frusemide was 99.98% and for amiloride hydrochloride was 100.09%. Developed method was found to be simple, accurate, precise and selective for simultaneous estimation of frusemide and amiloride hydrochloride in tablets

Phytoplasma diseases of medicinal crops

Phytoplasma diseases of medicinal plants occur worldwide and are of great concern. So far 19 different phytoplasma ribosomal groups encompassing various subgroups have been reported. The subgroup 16SrI-B phytoplasmas are the prevalent agents mainly detected in Europe, North America and Asia. Phytoplasma diseases of medicinal plants severely reduce yield and quality of crops along with the longevity of the plants. Changes in the composition of secondary metabolites are induced, while the levels of valuable phytochemicals are greatly affected. In contrast, an accumulation of pharmaceutically important compounds such as vinblastine and vincristine is reported in periwinkle upon phytoplasma infections. Important phytoplasma diseases of several medicinal plants with special reference to their impact on active biological constituents and secondary metabolites are reviewed. General information on geographic distribution, diagnostics, genetic diversity, natural transmission and management aspects of phytoplasmas infecting medicinal plants are also discussed